Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroendocrine Tumors 5 Carcinoid Tumor 2 Serotonin Syndrome 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Intestinal Obstruction 1 Gastro-enteropancreatic neuroendocrine tumor 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma 1 Adenoma, Islet Cell 1

Interventions

Prednisone 81 Docetaxel 64 enzalutamide 59 Abiraterone Acetate 54 Leuprolide 43 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 40 abiraterone 27 apalutamide 25 bicalutamide 22 pembrolizumab 20 radium Ra 223 dichloride 19 Zoledronic Acid 19 Prednisolone 19 Goserelin 19 darolutamide 18 Triptorelin Pamoate 13 sipuleucel-T 12 luprolide acetate gel depot 12 Androgen Antagonists 12 cabazitaxel 11 Dexamethasone 11 olaparib 10 Injections 10 gallium 68 PSMA-11 9 Pluvicto 9 Ipilimumab 9 orteronel 7 Standard of Care 7 Mitoxantrone 7 Lutetium-177 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313273 2019-11-22

POSEIDON

Ipsen

Phase 3 Terminated

3 enrolled 4 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡